Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594723 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
A Phase 2 study of Neoplasms, Hematologic, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT01594723 is a Phase 2 study of Neoplasms, Hematologic that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 110 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT01594723, a Phase 2 study of Neoplasms, Hematologic, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.
Conditions Studied
Interventions
- DRUG 120 mg LY2784544
Study Locations (20)
Tennessee
- Baptist Cancer Center - Memphis
- Sarah Cannon Cancer Center - Nashville
- Tennessee Oncology PLLC - Nashville
Florida
- Lakeland Regional Cancer Center - Lakeland
- Palm Beach Cancer Institue - West Palm Beach
New York
- Weill Cornell Medical College - New York
- Albert Einstein College of Medicine - The Bronx
Ohio
- Cleveland Clinic Foundation - Cleveland
- Mid Ohio Oncology Hematology - Columbus
Arkansas
- Highlands Oncology Group - Duplicate 2 - Rogers
California
- Providence St. Joseph's Medical Center - Burbank
Connecticut
- Norwalk Hospital - Norwalk
Illinois
- Ingalls Memorial Hospital - Harvey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-05-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594723
The ClinicalTrials.gov registry entry for NCT01594723 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Hematologic appearing as the primary indexed condition, and to 1 intervention - of which 120 mg LY2784544 is the first listed.
NCT01594723 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Tennessee, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01594723 about?
NCT01594723 is a clinical study titled "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms". The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure ...
What is the current status of trial NCT01594723?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2012-05-22. Estimated completion is 2026-12.
What conditions does trial NCT01594723 study?
This clinical trial studies the following conditions: Neoplasms, Hematologic.
What interventions are being tested in trial NCT01594723?
The interventions under investigation include: 120 mg LY2784544 (DRUG).
Who is sponsoring clinical trial NCT01594723?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01594723 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Hematologic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.